Repurposing existing drugs for COVID-19: an endocrinology perspective
September 2020
in “BMC Endocrine Disorders”
We don't know much about this study yet.
We're trying to become the world's largest resposity of hair loss research. You can help out the community by sending a PDF of this study here . Not sure how to get a study's PDF? You can email the authors of the study.Cited in this study
research Anti‐androgens may protect against severe COVID‐19 outcomes: results from a prospective cohort study of 77 hospitalized men
Anti-androgens, like finasteride, dutasteride, and spironolactone, may lessen the severity of COVID-19 in men, leading to fewer ICU admissions.
research A preliminary observation: Male pattern hair loss among hospitalized COVID‐19 patients in Spain – A potential clue to the role of androgens in COVID‐19 severity
Male pattern hair loss could hint at androgens affecting COVID-19 severity.
research Racial variations in COVID‐19 deaths may be due to androgen receptor genetic variants associated with prostate cancer and androgenetic alopecia. Are anti‐androgens a potential treatment for COVID‐19?
Genetic differences may affect COVID-19 deaths; anti-androgens could be potential treatment.
research What does androgenetic alopecia have to do with COVID‐19? An insight into a potential new therapy
Androgenetic alopecia linked to COVID-19 severity; drugs reducing androgen receptor activation may help.
research Safety concerns when using novel medications to treat alopecia
Consider benefits and risks of new alopecia treatments for safety.